Recent
- A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 Trial
- Elon Musk Excites Psychedelic Industry CEOs with This Tweet
- 5 Most Important Psychedelic Clinical Trials in 2022
- Ketamine Trial for Alcohol Use Disorder Delivers Very Promising Results
- Psychedelic Business Spotlight — January 7
- Psychedelic Business Spotlight: November 19
- Psychedelic Business Spotlight: October 29
- Psychedelic Business Spotlight: September 17, 2021
- Awakn Life Sciences CEO Details ‘Groundbreaking’ MDMA Discovery in Quest to Treat Addiction
- U.K. Psychedelic R&D Company Investigates MDMA, Ketamine for Addiction
Awakn Life Sciences
Public Company
[stockdio-historical-chart symbol="AWKN" stockExchange="NEO" palette="financial-light"]